Skip to main content


Figure 2 | Arthritis Research & Therapy

Figure 2

From: Methotrexate in chronic-recurrent calcium pyrophosphate deposition disease: no significant effect in a randomized crossover trial

Figure 2

Flow diagram of the study. Displays the study flow: 49 patients were screened, 26 corresponded to the inclusion and exclusion criteria and signed the study informed consent form, 21 (81%) finished the first treatment period and 20 (95%) the second treatment period. Overall, 25 patients completed the methotrexate (MTX) treatment period and 21 the placebo (PBO) treatment period.

Back to article page